29 July - Monday
Preliminary program - subject to change.
07:45 - 08:45
Concurrent Sessions: New Investigator Session and Focus Group Session
New Investigator Session
Chair: Bhagwat Prasad, University of Washington, Seattle, Washington, USA
All investigators within their first ten years of receiving their highest earned degree are welcome to attend and participate in this session. Continental breakfast will be available to attendees.
In this session, we will cover these topic areas and questions:
1. What current trends do you see in your area of work/research that may affect the job opportunities or research directions in the next 2-5 years?
2. How should a young investigator make his/herself stand out among their peers during the application or interview process?
3. What are the factors to consider when selecting to pursue a position/career in industry, academia, or government/regulatory?
Focus Group Session 1: Bioanalysis in ADME Science
Chair: Kevin Bateman, Merck and Co-Chair: Jens Sydor, Abbvie
The aims of this focus group are (a) to promote state-of-the-art analytical technologies to solve challenging issues faced in ADME studies and bioanalysis, (b) to enable industrial scientists to actively contribute to and participate at ISSX meetings and associated activities, and (d) to enhance synergy between industrial scientists and academic researchers.
Learn more about this focus group and join the online discussion before the meeting.
09:00 - 10:00
Plenary Lecture: How Technology, Big Data and Systems Approaches are Transforming 21st Century Healthcare
Leroy Hood, Providence St. Joseph Health, Renton, Washington, USA
10:00 - 11:00
ISSX Membership Meeting
ISSX President, Tom Baillie, University of Washington, Seattle, Washington, USA
ISSX Members are invited to attend this special member session to learn about Society updates and initiatives.
13:00 - 15:00
Concurrent Sessions: Symposia 1 and 2
Symposium 1: Personalized Medicine: Use of Pharmacogenomics and Other Patient-specific Factors to Individualize Drug Dosing and Treatment
Co-Chairs: Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom and Tsuyoshi Fukuda, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
Warfarin: A Paradigm for Individualized Dosing
Munir Pirmohamed, University of Liverpool, Liverpool, United Kingdom
Relevance of Transporter and Metabolic SNPs to Pediatric Treatment
Tsuyoshi Fukuda, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA
CPIC Guidelines and Implementation to Date
Kelly Caudle, St Jude Children’s Research Hospital, Memphis, Tennessee, USA
Personalised Treatment of Cancer
Howard McLeod, Moffitt Cancer Center, Tampa, Florida, USA
Symposium 2: State of the Art for Organs on Chips
Co-Chairs: Edward Kelly, University of Washington, Seattle, Washington, USA and Roos Masereeuw, Utrecht University, Utrecht, the Netherlands
Kidney Organoids for Disease Modeling and High Throughput Screening
Benjamin Freedman, University of Washington, Seattle, Washington, USA
Real-time Toxicity Assessment on Perfused 3D Epithelial Tubes
Bas Trietcsh, Mimetas, Lieden, Netherlands
"Tissues on Chips"- A Novel Tool for Toxicity and Efficacy Testing on Human Tissue
Bo Yeon Lee, National Institute of Health, NCATS, Bethesda, Maryland, USA
Biofabrication of Liver Constructs for Drug Toxicity Studies
Kerstin Schneeberger, Utrecht University, Utrecht, Netherlands
15:30 - 17:30
Concurrent Sessions: Symposia 3 and 4
Symposium 3: Quantitative Pharmacokinetic and Pharmacology Methods and Strategies in the Discovery and Development of Biotherapeutics
Co-Chairs: Hannah Jones, Pfizer Inc., Cambridge, Massachusetts, USA and Joe Balthasar, University of Buffalo, Buffalo, New York, USA
Development and Application of a PBPK Model for Large Molecules in Pfizer
Hannah Jones, Pfizer Inc., Cambridge, Massachusetts, USA
PBPK and PKPD Modeling to Investigate Engineered Antibodies
Tatsuhiko Tachibana, Chugai Pharmaceutical Co., Ltd., Shizuoka, Japan
PBPK Models for Predicting Human PK for Monoclonal Antibodies and Other Large Molecule Modalities
Iain Gardner, Certara UK Limited (Simcyp Division), Sheffield, United Kingdom
Systems PK/PD Model Informed Discovery and Development of Cancer Immunotherapy
Dhaval Shah, University of Buffalo, Buffalo, New York, USA
Symposium 4: Microbiome-Environment-Drug Interactions: Emerging Tools and Applications
Co-Chairs: Julia Yue Cui, University of Washington, Seattle, Washington, USA and Sumio Ohtsuki, Kumamoto University, Kumamoto, Japan
Impact of Intestinal Flora on Host Metabolism of Drug, Sugar and Lipid
Sumio Ohtsuki, Kumamoto University, Kumamoto, Japan
Activity-based Profiling of the Microbiome Response to Chemical Exposures
Aaron Wright, Pacific Northwest National Laboratory, Richland, Washington, USA
Impact of the Human Gut Microbiome on Drug Disposition
Peter Turnbaugh, NCATS, University of California San Francisco, San Francisco, California, USA
Developmental Reprogramming of the Gut Microbiota by Environmental Toxicants
Julia Yue Cui, University of Washington, Seattle, Washington, USA